DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

by Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Published 2016

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic a...

by Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Published 2016

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

by Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Published 2014